Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions

A method for treating, arresting, or causing regression of clinical symptoms of an ocular disease or disorder correlated with an elevated level of sphingosine-1-phosphate (S1P), comprising delivering to a tissue of a target eye of a subject having or believed to have an ocular disease or disorder correlated with an elevated level of S1P an amount of an anti-S1P antibody or antigen-binding fragment thereof which is effective to treat, arrest, or cause regression of clinical symptoms of the ocular disease or disorder correlated with an elevated level of SIP, wherein:

• (i) the ocular disease or disorder is characterized at least in part by aberrant neovascularization, aberrant fibrogenesis, fibrosis, scarring and/or inflammation;
• and
• (ii) the anti-S1P antibody or antigen binding antibody fragment comprises at least one heavy chain variable domain and at least one light chain variable domain, wherein each heavy chain variable domain comprises a first sequence of amino acid residues of sequence DHTIH (SEQ ID NO:
• 13), a second sequence of amino acid residues of sequence AISPRHDITKYNEMFRG (SEQ ID NO:
• 31), and (iii) a third sequence of amino acid residues of sequence GGFYGSTIWFDF (SEQ ID NO:
• 15), and wherein each light chain variable domain comprises a first sequence of amino acid residues of sequence ITTTDIDDDMN (SEQ ID NO:
• 10), a second sequence of amino acid residues of sequence EGNILRP (SEQ ID NO:
• 11) and a third sequence of amino acid residues of sequence LQSDNLPFT (SEQ ID NO:
• 12);
• whereby the severity of said disease or disorder is reduced.